Press Releases

The global nuclear medicine market is anticipated to grow at a 9.1% CAGR during the forecast period. Molecular imaging is a technique that uses molecules as biomarkers for specific molecular processes to assess the development and/or progression of the disease by adopting radiopharmaceuticals. During the projected period, this is expected to drive the nuclear medicine market. The use of radioactive chemicals in research, diagnosis, and treatment is referred to as nuclear medicine. The rising prevalence of cancer and cardiovascular diseases and reduce the demand-supply gap of Mo-99 are the key drivers for the nuclear medicine market. Furthermore, the increased adoption of SPECT and PET applications and rising public awareness about healthcare will accelerate the growth of the market. Nevertheless, the initiatives by the government and increasing funds to develop new techniques will drive the growth of the nuclear medicine market.

In May 2021, Curium has acquired IASON, an Austrian radiopharmaceuticals company, expanding its European footprint for its extensive line of life-saving diagnostic products. Curium has now acquired a second positron-emission-tomography (PET) radiopharmaceutical company this year, following the acquisition of M2i, a leading Irish PET company, earlier this year.

The COVID-19 pandemic has had an adverse impact on the nuclear medicine market as in line with clinical preparation efforts, scientific research operations at academic medical facilities and colleges were urgently halted in order to reduce the spread of disease to research staff and individuals with whom they may come into contact. However, the rising demand for precise diagnosis and increased positive cases of coronavirus has led to the adoption of nuclear medicines as coronavirus affects the respiratory system severely, hence there is a need for nuclear medicine to treat and diagnose the problems of the respiratory system.

Browse 53 market data Tables and 35 Figures spread through 250 Pages and in-depth TOC on " Nuclear Medicine Market by Type (Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals), Therapeutic Nuclear Medicine (Alpha Emitters and Beta Emitters), and Brachytherapy Isotopes (Iodine-125, Palladium-103, Cesium-131, Iridium-192, and Other Brachytherapy Isotopes), by Application (SPECT Applications (Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, and Others), PET Applications (Oncology, Cardiology, Neurology, and Others), and Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, and Other Indications), by End User (Hospitals and Diagnostic Centers, and Research Institutes), and Region - Global Forecast to 2030"

By type, the diagnostic nuclear medicine segment will contribute to the largest share during the forecast period.

Based on type, the global nuclear medicine market is separated into diagnostic nuclear medicine and therapeutic nuclear medicine, and brachytherapy isotopes. The diagnostic segment dominates the nuclear medicine market owing to the non-invasiveness and rising prominence of cardiovascular diseases and early diagnosis. Movement disorders, epilepsy, brain tumors, dementia, stroke, and neural plasticity are some of the clinical neurology applications for PET imaging radioisotopes. Early detection of brain metastases, Parkinson's syndromes, and neurodegenerative disorders like Alzheimer's disease are among the future applications. Because of raising public awareness of radioisotopes and rising rates of chronic diseases such as cancer and cardiovascular disease, the market for radioisotopes is predicted to grow in emerging regions. As a result of these factors, the market is likely to rise rapidly in the next years.

Global Nuclear Medicine Market Segmentation Analysis

Discover More About This Report, Download A Free Sample Copy of Global Nuclear Medicine Market

“North America to hold the largest regional market share in 2022.”

North America dominates the nuclear medicine market as the United States is the largest consumer for radioisotopes and Canada is the largest producer of Tc-99m. Furthermore, increased investment in research and development activities by the government to support the adoption of medical isotopes will propel the growth of the nuclear medicine market in the region.

Some of the major players in the global Nuclear Medicine market include Cardinal Health, General Electric Company, Bayer AG, Curium, Lantheus Medical Imaging, Inc., Medtronic, Bracco Diagnostic Inc., Nordion (Canada) Inc., Eczacýbaþý-Monrol Nuclear Products, and Advanced Accelerator Applications.

Scope of the Report

Global Nuclear Medicine Market Coverage

Type Insight and Forecast 2018-2030

• Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • PET Radiopharmaceuticals
• Therapeutic Nuclear Medicine
  • Alpha Emitters
  • Beta Emitters
• Brachytherapy Isotopes
  • Iodine-125
  • Palladium-103
  • Cesium-131
  • Iridium-192
  • Other Brachytherapy Isotopes

Application Insight and Forecast 2018-2030

• SPECT Applications
  • Cardiology
  • Bone Scans
  • Thyroid Applications
  • Pulmonary Scans
  • Others
• PET Applications
  • Oncology
  • Cardiology
  • Neurology
  • Others)
• Therapeutic Applications
  • Thyroid Indications
  • Bone Metastasis
  • Lymphoma
  • Endocrine Tumors
  • Other Indications

End User Insight and Forecast 2018-2030

• Hospitals and Diagnostic Centers
• Research Institutes

Geographical Segmentation

Nuclear Medicine Market by Region

North America

• By Type
• By Application
• By End User
• By Country – U.S., Canada, and Mexico

Europe

• By Type
• By Application
• By End User
• By Country – Germany, U.K., France, Italy, Spain, Russia, and Rest of Europe

Asia-Pacific (APAC)

• By Type
• By Application
• By End User
• By Country – China, Japan, India, South Korea, and Rest of Asia-Pacific

Rest of the World (RoW)

• By Type
• By Application
• By End User
• By Country – Brazil, Saudi Arabia, South Africa, U.A.E., and Other Countries